Evidence map›Paper›PMID 33673346›Full record

ArticleInternational journal of molecular sciences2021

Evidence for 2-Methoxyestradiol-Mediated Inhibition of Receptor Tyrosine Kinase RON in the Management of Prostate Cancer.

Izhar Singh Batth, Shih-Bo Huang, Michelle Villarreal, Jingjing Gong, Divya Chakravarthy, Brian Keppler, Sridharan Jayamohan, Pawel Osmulski, Jianping Xie, Paul Rivas and 7 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Phenomics (Cham, Switzerland) · 2024
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Izhar Singh BatthDepartment of Molecular Medicine, University of Texas Health, San Antonio, TX 78229, USA.
Shih-Bo HuangDepartment of Molecular Medicine, University of Texas Health, San Antonio, TX 78229, USA.ORCID 0000-0002-1048-2344
Michelle VillarrealDepartment of Molecular Medicine, University of Texas Health, San Antonio, TX 78229, USA.ORCID 0000-0002-9500-9299
Jingjing GongDepartment of Molecular Medicine, University of Texas Health, San Antonio, TX 78229, USA.
Divya ChakravarthyDepartment of Molecular Medicine, University of Texas Health, San Antonio, TX 78229, USA.
Brian KepplerDepartment of Molecular Medicine, University of Texas Health, San Antonio, TX 78229, USA.
Sridharan JayamohanDepartment of Molecular Medicine, University of Texas Health, San Antonio, TX 78229, USA.
Pawel OsmulskiDepartment of Molecular Medicine, University of Texas Health, San Antonio, TX 78229, USA.ORCID 0000-0002-5359-9200
Jianping XieDepartment of Molecular Medicine, University of Texas Health, San Antonio, TX 78229, USA.
Paul RivasDepartment of Molecular Medicine, University of Texas Health, San Antonio, TX 78229, USA.
Roble BedollaDepartment of Molecular Medicine, University of Texas Health, San Antonio, TX 78229, USA.
Michael A LissUrology, University of Texas Health, San Antonio, TX 78229, USA.
I-Tien YehPathology, University of Texas Health, San Antonio, TX 78229, USA.
Robert ReddickPathology, University of Texas Health, San Antonio, TX 78229, USA.
Hiroshi MiyamotoDepartment of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA.ORCID 0000-0001-7610-7769
Rita GhoshUrology, University of Texas Health, San Antonio, TX 78229, USA.
Addanki P KumarDepartment of Molecular Medicine, University of Texas Health, San Antonio, TX 78229, USA.ORCID 0000-0001-5596-6265
The University of Texas Health Science Center at San Antonio · USUniversity of Rochester Medical Center · US

Funding

Oxidative stress in prostate cancer: Efficacy of antioxidants in Nkx3.1; Pten modR01CA149516 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI GHOSH, RITA · 2010 to 2014
$1.6M
Towards identification of prognostic gene sets in breast cancer: The E2197 TrialR21CA150166 · NCI · EMORY UNIVERSITY · PI LEYLAND-JONES, BRIAN · 2010 to 2011
$374k
Cancer Prevention and Research Institute of Texas RP 150166 and 190012NCI NIH HHS CA149516U.S. Department of Veterans Affairs I 01 BX003876
6 · The paper itself

Abstract

2-Methoxyestradiol (2-ME

Indexed as

Drug RepositioningNeoplasm ProteinsProstatic NeoplasmsReceptor Protein-Tyrosine Kinases2-MethoxyestradiolAnimalsHumansMaleMicePC-3 Cells2-MethoxyestradiolNeoplasm ProteinsReceptor Protein-Tyrosine KinasesRON protein2-methoxyestradiolatomic force microscopybile acidscastration-resistant prostate cancerepithelial mesenchymal transitionmechanical propertiesprostate cancer disparitiesreceptor tyrosine kinaseRON

Identifiers

PMID33673346
PMCPMC7918140
OpenAlexW3133118477

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.